BACKGROUND Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases myocardial function in
T he morbidity and mortality associated with acute heart failure (AHF) remain substantial with few therapeutic advances in recent decades, a finding suggesting that new AHF therapies represent a major unmet medical need (1) . Although AHF is a heterogeneous condition, impaired cardiac contractility is a central pathophysiological feature in at least one-half of these patients and may be a key therapeutic target. However, trials of many inotropic agents have failed to demonstrate either efficacy or safety because of adverse effects such as arrhythmias, hypotension, myocardial ischemia, and increased mortality (2); consequently, recent guidelines limit the use of these agents to patients with cardiogenic shock or evidence of marked end-organ hypoperfusion (3, 4) .
Omecamtiv mecarbil (OM) is a selective small molecule activator of cardiac myosin that prolongs myocardial systole (5) . In contrast to traditional inotropes, which increase myocardial contraction rate and shorten systole duration, OM increases stroke volume by extending the duration of systole without changing the velocity of myocardial contraction (i.e., no change in pressure with respect to time, þdP/dt). In pre-clinical models, OM increased cardiac contractility and stroke volume without apparent effects on myocardial oxygen demand (6) or cardiac myocyte calcium transients (5) , which are putative mechanisms of harm for traditional inotropic agents, such as beta-agonists and phosphodiesterase-3 inhibitors. In healthy volunteers (7) and in patients with chronic heart failure (CHF) and systolic dysfunction (8) We vouch for the completeness and accuracy of the data and the analyses as well as the fidelity of the study to the protocol.
PATIENTS. We enrolled men and women 18 through 85 years of age with a history of CHF and left ventricular (LV) ejection fraction (EF) #40%, who were admitted for AHF and had dyspnea at rest or with minimal exertion and had increased plasma concentrations of B-type natriuretic peptides (BNPs):
BNP $400 pg/ml or N-terminal (NT)-proBNP $1,600 pg/ml; BNP $600 pg/ml or NT-proBNP $2,400 pg/ml with atrial fibrillation. Eligible patients had persistent PROCEDURES. ATOMIC-AHF enrolled 3 sequential cohorts (w200 patients per cohort) (Online Figure 1) targeting mean OM plasma concentrations at 48 h of 115 ng/ml, 230 ng/ml, and 310 ng/ml and using 3 escalating dose regimens (Online Appendix). As specified by protocol, enrollment was paused between cohorts to allow for a data monitoring committee safety data review; enrollment resumed on the committee's recommendation. Through PK/PD modeling, these doses were designed to attain progressively higher target plasma concentrations, with the low dose anticipated to have minimal cardiac effect, an intermediate dose, and the high dose chosen to maximize the PD response and minimize occurrence of excessive plasma concentrations in most patients (>99%).
Patients received OM or placebo infused over 48 h and had to remain hospitalized for at least 24 h after infusion termination (Online Figure 2 ). Patients were evaluated in person during hospitalization and on day 30 and by telephone at 6 months for vital status.
OUTCOMES. The primary efficacy endpoint evaluated dyspnea improvement using a patient-reported Thus, the primary endpoint was not achieved.
However, as noted earlier, because of the monthslong time delays among cohorts for data monitoring committee reviews, differences in time to randomization, region of enrollment, and baseline characteristics were observed among the cohorts, so a pre-specified supplemental analysis of comparisons between placebo and OM groups within each cohort was performed There were no statistically significant differences for any of the secondary endpoints when OM treatment cohorts were compared with the pooled placebo ( Table 2) Table 1 ).
Cardiac troponin I (cTnI) was intensively moni- Values are mean AE SD, n (%), or median (interquartile range). *Denotes significant differences (p < 0.05) between individual placebo cohorts. †Smaller value indicates better dyspnea condition.
ACE ¼ angiotensin-converting enzyme; AF ¼ atrial fibrillation; AHF ¼ acute heart failure; BP ¼ blood pressure; eGFR ¼ estimated glomerular filtration rate; HF ¼ heart failure; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; Nonwhite ¼ includes American-Indian or Alaska Native, Asian, Black or African-American, Native Hawaiian or Pacific Islander, Mixed Race or Other; NRS ¼ numerical rating scale; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; NYHA ¼ New York Heart Association; OM ¼ omecamtiv mecarbil; URL ¼ upper reference limit. Teerlink et al.
was nearly identical to that seen in the previous 2 studies. These findings demonstrated that this mechanism of action is operative in AHF and provides evidence that this effect translated into a physiological benefit with a significant reduction in LVESD, a finding consistent with an improvement in cardiac performance and related to improved long-term survival (12) . Although SET is inversely related to heart rate, it has also been long recognized that patients with reduced cardiac output or EF have decreased SETs (13) , and thus OM may be viewed as effectively normalizing ejection time.
The most common presenting symptom in patients with AHF, dyspnea at rest or with minimal exertion, remains a clinically meaningful endpoint (14) . OM increased cardiac output and reduced LV filling pressures in animal models (5, 6) , and it improved cardiac function in humans (7, 8) , thereby providing a mechanism for dyspnea relief in patients. Previous trials suggested that selection of symptomatic patients and objective signs of congestion early in their hospital course provide the best opportunity to demonstrate a clinical benefit on dyspnea (15, 16) . In ATOMIC-AHF, dyspnea relief was evaluated by a responder variable requiring early and sustained improvement in dyspnea compared with standard therapy without evidence of clinical worsening within the first 48 h. In an attempt to increase the power of this phase II study for a symptom endpoint, the primary analysis pre-specified comparisons LV ¼ left ventricular; PK ¼ pharmacokinetics; other abbreviations as in Table 1 . Number of subjects reporting AEs of ischemic heart disease, MI, increased troponins Values are n (%). *Cardiac failure includes both "Cardiac failure" and "Cardiac failure congestive" preferred terms.
AE ¼ adverse event; SVT ¼ supraventricular tachyarrhythmia; VT ¼ ventricular tachyarrhythmia; other abbreviations as in Table 1 . clinical studies (7, 8) . In ATOMIC-AHF, OM decreased heart rate versus placebo and did not increase risk of SVT or VT. OM improved left atrial function and reduced volumes in healthy volunteers; such an effect could reduce the propensity to atrial arrhythmias (7).
Worsening HF during initial hospitalization has emerged as a clinically important event with both short-and long-term prognostic implications (19, (27) (28) (29) . In ATOMIC-AHF, too few events occurred to evaluate this endpoint meaningfully, although there were numerically fewer worsening HF events among patients who received OM than in patients who received placebo within each cohort. Both milrinone (25) and levosimendan (26) have been associated with increases in mortality; in the current study, 180-day all-cause mortality was 12.9% in the placebo and 12.5% in the OM group. More data are required to assess differences in mortality.
STUDY LIMITATIONS. ATOMIC-AHF was a phase II, dose-finding study that was underpowered to assess the potential impact of OM on clinical outcomes. In addition, the serial enrollment of the cohorts separated by months resulted in differences in the patient populations and placebo response rates among the Maximal concentrations (C max ) of omecamtiv mecarbil in plasma did not predict maximal change from baseline in troponin concentrations (range À40 to 100 ng/ml). The inset presents the same data with an expanded y-axis (range À4 to 4 ng/ml) excluding outliers.
Solid circles ¼ 1 patient; lines in inset ¼ linear regression and 95% confidence intervals.
Max ¼ maximal. 
